This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okumura, M. Articles by Amino, N. Search for Related Content PubMed PubMed Citation Articles by Okumura, M. Articles by Amino, N.

Increased Serum Concentration of Soluble CD30 in Patients with Graves’ Disease and Hashimoto’s Thyroiditis¹

Department of Laboratory Medicine, Osaka University Medical School, 2–2 Yamadaoka, Suita, Osaka 565, Japan

Address all correspondence and requests for reprints to: Yoh Hidaka M.D., Department of Laboratory Medicine, Osaka University Medical School, 2–2 Yamadaoka, Suita, Osaka 565, Japan.

This study investigated serum levels of the soluble form of CD30 (sCD30), which is mainly secreted from T helper 2(Th2) cells, in autoimmune thyroid diseases. The possible relationship of sCD30 to autoantibody production was also evaluated. Serum levels of sCD30 were determined by an enzyme-linked immunosorbent assay in 71 patients with Graves’ disease, 37 patients with Hashimoto’s thyroiditis, and 21 normal donors. Compared with normal subjects (7.1 ± 4.5 U/mL), sCD30 was increased in patients with Graves’ disease (29.2 ± 25.2 U/mL, P < 0.0001) and in patients with Hashimoto’s thyroiditis (29.9 ± 26.9 U/mL, P < 0.0001). In Graves’ disease, sCD30 levels were higher in thyrotoxic patients (41.7 ± 31.2 U/mL, P < 0.001) than in remission patients (15.8 ± 11.0 U/mL), and a significant correlation was observed between sCD30 levels and serum activities of TSH receptor antibody (r = 0.444, P < 0.0001). In Hashimoto’s thyroiditis, sCD30 levels were higher in patients with transient destructive thyrotoxicosis caused by the aggravation of the disease (48.8 ± 34.4 U/mL, P < 0.05) than in euthyroid patients (24.2 ± 19.4 U/mL). These data suggest that serum sCD30 is a valuable marker of disease activity and support an important role of the Th2-type immune response in the pathogenesis in Graves’ disease and Hashimoto’s thyroiditis.

This article has been cited by other articles:

				A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]

				R. Gerli, C. Lunardi, and C. Pitzalis Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis Rheumatology, December 1, 2002; 41(12): 1341 - 1345. [Full Text] [PDF]

				M. E. Kadin Regulation of CD30 Antigen Expression and Its Potential Significance for Human Disease Am. J. Pathol., May 1, 2000; 156(5): 1479 - 1484. [Full Text] [PDF]